DiaMedica Therapeutics In... (DMAC)
NASDAQ: DMAC
· Real-Time Price · USD
4.05
0.05 (1.25%)
At close: May 15, 2025, 3:59 PM
4.07
0.37%
After-hours: May 15, 2025, 04:05 PM EDT
1.25% (1D)
| Bid | 3.65 |
| Market Cap | 173.89M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.44M |
| EPS (ttm) | -0.6 |
| PE Ratio (ttm) | -6.76 |
| Forward PE | -5.36 |
| Analyst | Strong Buy |
| Ask | 4.34 |
| Volume | 111,254 |
| Avg. Volume (20D) | 96,363 |
| Open | 3.99 |
| Previous Close | 4.00 |
| Day's Range | 3.88 - 4.22 |
| 52-Week Range | 2.14 - 6.82 |
| Beta | 1.29 |
About DMAC
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol DMAC
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for DMAC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-13.02%
DiaMedica Therapeutics shares are trading lower fo...
Unlock content with
Pro Subscription
10 months ago
+30.97%
DiaMedica Therapeutics shares are trading higher. The company announced a $11.8 million private placement and will issue 4.720 million shares at $2.50 per share.
1 month ago · seekingalpha.com
DiaMedica Therapeutics Inc. (DMAC) Q4 2024 Earnings Call TranscriptDiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q4 2024 Earnings Conference Call March 18, 2025 8:00 AM ET Company Participants Rick Pauls - President and CEO Lorianne Masuoka - CMO Scott Kellen - CFO Conf...
2 months ago · businesswire.com
DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of DirectorsMINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the election of ...